Thank you! You made our website update possible!

Bladder Cancer Canada is thrilled to announce that our website, bladdercancercanada.org, has been refreshed with updated information and new content!

Thanks to your generous donations, we were able to improve the user experience with enhanced graphics and a more intuitive layout. Explore the new features and resources we’ve added to better serve our community.

Save the date! Giving Tuesday is December 3rd

On December 3rd, we invite you to join us for #GivingTuesday, the worlds largest generosity movement.  

With a 77% survival rate if caught early, awareness of the signs and symptoms of bladder cancer is critical.

This #GivingTuesday we have set a goal of $15,000 to help fund the creation of a new Hematuria Education Resource to increase awareness of hematuria and the importance of bladder cancer testing. 

With your help, patients experiencing blood in the urine will be better equipped to advocate for bladder cancer testing, and more cases will be caught and treated earlier. 

An integrated immune monitoring approach for sex associated B cell exhaustion in BCG unresponsive NMIBC

This project focuses on improving outcomes for bladder cancer patients, especially those unresponsive to Bacillus Calmette-Guerin (BCG) therapy. Focused on understanding B cell behavior—especially the role of “exhausted” B cells in promoting cancer recurrence—researchers are exploring how specific B cell populations may influence relapse after BCG treatment. Early results reveal that higher densities of certain B cells are linked with rapid recurrence, especially among female patients, who often experience shorter recurrence-free intervals than male patients. This difference may stem from underlying sex-based immune responses, making this study crucial for addressing treatment disparities. Through analysis of patient blood and tissue samples, the team is identifying biomarkers associated with early recurrence, which could guide personalized treatments.

Leveraging cutting-edge techniques such as single-cell RNA sequencing, the study will map immune cell changes over time to create an early detection system for high-risk individuals. This pioneering approach not only addresses gender-related differences in bladder cancer outcomes but also establishes a foundation for customized interventions, aiming to improve survival rates and quality of life for all bladder cancer patients.

Note: This summary was written from the research proposal titled 'An integrated immune monitoring approach for sex associated B cell exhaustion in BCG unresponsive NMIBC', by Madhuri Koti, D. Robert Siemens (Co-Applicants) David M. Berman, Peter Black, John Sfakianos (collaborators)

Latest Advances in Bladder Cancer Treatment

Join us on December 3 at 7pm ET, for a webinar featuring Dr. Nimira Alimohamed and Dr. Bernie Eigl, who will provide an in-depth overview of enfortumab vedotin plus pembrolizumab, the newly approved treatment for advanced bladder cancer.

In this session, you'll learn about the clinical trial data that led to its approval, gain a better understanding of the treatment process, and explore potential side effects. If you have questions about this new therapy, this is a great opportunity to get answers from experts in the field. Don't miss out. 

For more information or to register, visit our EVENTS PAGE at bladdercancercanada.org.

We are also so grateful to our amazing volunteers – Georgette, Elizabeth, Angela, and Ronil – for all their hard work and support. 💖 

We look forward to seeing you at our next event in 2025! Stay tuned! 

Catch Up on latest BCC Content

Bladder Cancer Basics: Essential Knowledge for Patients and Caregivers with Dr. Paul Toren 

Disability Tax Credit for Bladder Cancer Patients with Rosemary Hill (RN) & Cheryl Carley (CPA) 

What's in Your Bladder Cancer Pathology Report? with Dr. David Berman (MD, PhD) 

Follow us online

Please join us on social media where we share updates and photos from our bladder cancer community. These social media sites are a great resource for patients, survivors, and caregivers.

Copyright © 2024 Bladder Cancer Canada. All rights reserved. You are receiving this email because you have registered on our website or expressed an interest in receiving more information about bladder cancer or Bladder Cancer Canada.